Morgan Stanley Upgrades Centessa Pharmaceuticals to Overweight, Raises Price Target to $26
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley has upgraded Centessa Pharmaceuticals to Overweight and increased its price target from $11 to $26, indicating a positive outlook for the company's stock.
September 19, 2024 | 10:12 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Morgan Stanley has upgraded Centessa Pharmaceuticals to Overweight and raised its price target from $11 to $26, suggesting a positive short-term outlook for the stock.
The upgrade from Equal-Weight to Overweight by Morgan Stanley, along with a significant increase in the price target, indicates strong confidence in Centessa Pharmaceuticals' future performance. This is likely to positively impact the stock price in the short term as investors react to the analyst's optimistic outlook.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100